Generic Drugs

The role of generics

Reducing health costs and at the same time improving care: this problem, common to many countries, finds a partial solution in generic drugs, whose development is receiving increasing support from government legislations and authorities - support which is, moreover, proving to be a stimulus to the entire pharmaceutical industry.
 
Less expensive and better health care
From 30 to 50% less expensive than the reference drug, the generic product is also an updated version of it: more than 10 years after the launch of the original drug, it is only to be expected that the new drug will incorporate technological advances. Moreover, the constant quest is to achieve better therapeutic efficacy from molecules by improving their pharmaceutical formulation.

More and more "genericable®" drugs
More and more molecules are becoming available due to the expansion of pharmaceutical research and a favourable political climate. This "bank" of molecules makes it possible to increase the number of generics, particularly since legislation, e.g. in France, strongly encourages pharmacists to "substitute" a generic for the reference drug prescribed. Moreover, the development of generics is a strong incentive for big research laboratories to concentrate their resources on the development of new molecules.

 
The generics culture

Creation of a generic drug demands, in addition to scientific knowledge and industrial know-how, a specific marketing dimension and a command of patents : in this "generics" culture, CLL PHARMA is one of the only movers on the market able to offer the major laboratories the "development engineering" they often lack.
 
Finding the way through the maze of patents
The prerequisite for a drug to be "genericable®" is that it must be on the point of becoming public property, either because the patent is due to expire or because it is invalid. A mastery of patent law is one of CLL PHARMA's trump cards, and the prize which it was awarded in 1998 by the INPI (French Patent Office) provided an additional incentive.

Finding the "genericable®" drugs
Taking the French pharmaceutical market as an example, of the 7,500 reference drugs it comprises, all "genericable®" molecules are not equally suitable: a selective evaluation has to be made to spot which of them may become good generics, in terms of profitability and market potential.
This is a branch of know-how that the CLL PHARMA team has at its finger-tips.

The right sourcing
CLL PHARMA' s knowledge of the worldwide fine chemicals market is the result of its long experience and its network, two of the company's greatest assets, notably in the field of fermentation chemistry and biotechnologies.
Our know-how covers, inter alia, the transfer of files meeting the highest standards (Food and Drug Administration, European Union, etc.) and support from our teams until registration is obtained and the finished product is supplied.